NUSINERSEN
nusinersen 12 mg/5 mL intrathecal injection, 5 mL vial
NUSINERSEN (14090N)
14090N
Manner of administration:Injection
Restriction
Indication: Spinal muscular atrophy (SMA)
Treatment phase: Continuing/maintenance treatment of a patient commenced on this drug under the pre-symptomatic
SMA (3 copies of the SMN2 gene) listing
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 0 | DPMQ: $104,548.88 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Spinraza | |||||